5 months ago
3
Biotechnology large Biocon connected Saturday (December 6, 2025) said it volition afloat integrate Biocon Biologics with itself, successful a woody valuing the biologics portion astatine $5.5 billion.
As portion of the transaction, Biocon volition get the remaining involvement successful Biocon Biologics Limited from Serum Institute Life Sciences, Tata Capital Growth Fund II and Activ Pine LLP done a stock swap, valuing Biocon Biologics astatine $5.5 billion, the Bengaluru-based institution said successful a regulatory filing.
The share-swap ratio has been fixed astatine 70.28 Biocon shares for each 100 Biocon Biologics shares, astatine a stock terms of ₹405.78 per Biocon share, it added.
Further, Biocon volition get the residual involvement held by Mylan Inc (Viatris) for a full information of $815 million, of which $400 cardinal volition beryllium payable successful currency and $415 cardinal done a stock swap, it added.
Biocon is constituting a governance assembly chaired by Kiran Mazumdar-Shaw and a modulation and integration absorption committee, led by Biocon Biologics CEO and Managing Director (MD) Shreehas Tambe, to guarantee a seamless integration.
The institution said its committee has besides approved raising to ₹4,500 crore successful further superior done a Qualified Institutional Placement (QIP), taxable to shareholder approval.
The proceeds of the QIP volition beryllium chiefly utilised to wage the currency constituent to Viatris.
"The integration of Biocon Biologics into Biocon Limited represents the adjacent section successful our evolution. Strategically, Biocon volition beryllium 1 of the fewer companies offering some biosimilars and generics astatine a planetary scale," Biocon Executive chairperson Kiran Mazumdar-Shaw said.
“As the lone institution with biosimilar insulins and generic GLP-1 peptides, Biocon is uniquely positioned to code the needs of patients surviving with diabetes comprehensively,” she added.
"Together with our combined oncology and immunology portfolios, this creates a differentiated offering addressing the world's astir pressing healthcare needs,” Ms. Mazumdar-Shaw stated.
Biocon Biologics CEO Mr. Tambe to pb integrated business
“Mr. Tambe volition pb the modulation and integration absorption committee and volition instrumentality implicit arsenic the CEO & MD of the combined business, taxable to requisite approvals,” she said.
“This integration enables Biocon to harness the combined strengths of its generics and biosimilars businesses crossed countries,” the institution stated.
Biocon Biologics ranks among the apical 5 planetary biosimilar players by revenue, with 10 commercialised products crossed cardinal markets, portion Biocon's generics concern offers implicit 90 products.
The integration process is expected to beryllium completed by March 31, 2026. The integration marks a pivotal measurement successful combining the businesses to leverage the planetary commercialized infrastructure, simplify the firm structure, and fortify Biocon's planetary presumption to pb successful diabetes, oncology and immunology – therapeutic areas that unneurotic relationship for astir 40% of planetary pharmaceutical revenues.
“As the lone institution operating globally with some biosimilar insulins and generic versions of analyzable peptides, including GLP-1s, Biocon is uniquely poised to code the rapidly expanding 'diabesity' market,” it said.
Post the integration and upon execution of the indispensable documentation, receipt of approvals from the Nomination & Remuneration Committee (NRC) and the Board, Mr. Tambe volition instrumentality connected the relation of the CEO & MD, and Kedar Upadhye volition instrumentality connected the relation of main fiscal serviceman of the combined business.
“Siddharth Mittal, CEO & MD, Biocon Ltd., volition modulation into a enactment relation wrong the Group,” the institution stated.
